Citizens Financial Group Inc. RI Has $4.20 Million Holdings in Pfizer Inc. (NYSE:PFE)

Citizens Financial Group Inc. RI boosted its position in Pfizer Inc. (NYSE:PFE) by 40.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 145,969 shares of the biopharmaceutical company’s stock after buying an additional 42,202 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Pfizer were worth $4,202,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Golden State Equity Partners grew its position in Pfizer by 134.2% in the 4th quarter. Golden State Equity Partners now owns 25,493 shares of the biopharmaceutical company’s stock worth $734,000 after purchasing an additional 14,607 shares during the last quarter. Raab & Moskowitz Asset Management LLC grew its position in Pfizer by 1.4% in the 4th quarter. Raab & Moskowitz Asset Management LLC now owns 133,747 shares of the biopharmaceutical company’s stock worth $3,851,000 after purchasing an additional 1,884 shares during the last quarter. Spinnaker Trust grew its position in Pfizer by 78.3% in the 4th quarter. Spinnaker Trust now owns 86,160 shares of the biopharmaceutical company’s stock worth $2,481,000 after purchasing an additional 37,829 shares during the last quarter. K.J. Harrison & Partners Inc grew its position in Pfizer by 13.4% in the 4th quarter. K.J. Harrison & Partners Inc now owns 41,801 shares of the biopharmaceutical company’s stock worth $1,203,000 after purchasing an additional 4,952 shares during the last quarter. Finally, Callan Capital LLC grew its position in Pfizer by 8.8% in the 4th quarter. Callan Capital LLC now owns 11,576 shares of the biopharmaceutical company’s stock worth $333,000 after purchasing an additional 932 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research firms have issued reports on PFE. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Monday, April 15th. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, TD Cowen lowered shares of Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $36.33.

Pfizer Price Performance

PFE stock traded up $0.14 during trading on Friday, hitting $25.40. 46,526,457 shares of the stock traded hands, compared to its average volume of 34,120,812. Pfizer Inc. has a one year low of $25.20 and a one year high of $40.37. The stock has a market cap of $143.83 billion, a price-to-earnings ratio of 70.56, a P/E/G ratio of 1.14 and a beta of 0.61. The company has a 50 day simple moving average of $26.96 and a 200 day simple moving average of $28.42. The company has a current ratio of 0.91, a quick ratio of 0.69 and a debt-to-equity ratio of 0.69.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The firm had revenue of $14.25 billion during the quarter, compared to the consensus estimate of $14.37 billion. During the same period last year, the firm posted $1.14 EPS. The firm’s quarterly revenue was down 41.3% on a year-over-year basis. Equities analysts expect that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be paid a $0.42 dividend. This represents a $1.68 dividend on an annualized basis and a dividend yield of 6.61%. The ex-dividend date of this dividend is Thursday, May 9th. Pfizer’s dividend payout ratio is presently 466.67%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.